Kissei
| ISIN | JP3240600001 |
|---|---|
| Industry | Pharmaceutical products, therapeutic and care foods |
| Founded | August 9, 1946 |
| Headquarters | Matsumoto, Nagano , Japan |
Key people | Mutsuo Kanzawa (CEO) |
Number of employees | 1504 |
| Website | www |
Kissei Pharmaceutical is a pharmaceutical company based in Matsumoto, Nagano, Japan. Products discovered or developed by Kissei include:[1]
- Difelikefalin
- Fostamatinib (trade name Tavalisse)
- Linzagolix
- Mitiglinide (Glufast)
- Remogliflozin etabonate
- Silodosin (Urief)
- Tranilast (Rizaben)
In March 2020, Kissei and CG Oncology, Inc. announced an exclusive license, development, and commercialization agreement for CG's oncolytic immumotherapy drug CG0070. The agreement covered Japan, South Korea, Taiwan, and other Asian countries, but not China.[2]
References
- ↑ "English Home".
- ↑ "CG Oncology Announces License and Commercialization Agreement with Kissei Pharmaceutical Co., Ltd. for CG0070 in Japan and Other Asian Countries". www.businesswire.com. 2020-03-27. Retrieved 2020-06-04.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.